5th Floor, Rajapushpa Summit
Nanakramguda Rd, Financial District, Gachibowli
Hyderabad, Telangana - 500008
The Ovarian Cancer Diagnostics and Therapeutics Market is segmented by Cancer Type (Epithelial Ovarian Tumors, Ovarian Germ Cell Tumors, and Others), Modality (Diagnosis and Therapeutics), and Geography.
2018 - 2026
Fastest Growing Market:
Ovarian cancer is the fifth most common cause of cancer deaths in women, globally, and the tenth most common cancer among women in the United States. The incidences of ovarian cancer are high in women aged 55-64 years. The major symptoms of ovarian cancer include bloating, pelvic and abdominal pain, difficulty in eating, and urinary symptoms. According to the United States Census Bureau, women above 60 years of age account for almost 57% of all ovarian cancer incidences and 75% of all ovarian cancer-related deaths worldwide, with a median age at diagnosis being 63 years and the median age at death being 70 years. Thus, the increasing geriatric population is driving the growth of the ovarian cancer diagnostics and therapeutics market. An accurate diagnosis for ovarian cancer is critical, as in most cases, cancer already begins to spread to the lymph nodes and outside of the pelvis at the time of diagnosis. Ovariancancerawareness.org reports that the five-year survival rate for ovarian cancer with early-stage 1 detection is 93% and that most new cases of ovarian cancer are diagnosed at stage 3 or later, leaving little time as well as room for an accurate diagnosis.
Ovarian cancer is a type of cancer that begins in the ovaries. There are several types of ovarian cancer, Epithelial ovarian cancer is the most common type of ovarian cancer. Ovarian cancer is caused by uncontrollable cell growth in the ovarian tissue. It is a growing concern and one of the most common causes of death in women across the world.
|By Cancer Type|
|Epithelial Ovarian Tumors|
|Ovarian Germ Cell Tumors|
Report scope can be customized per your requirements. Click here.
Computed Tomography (CT) is an imaging procedure that uses special X-ray equipment to create detailed pictures, or scans, of areas inside the body. It is also called computerized tomography and computerized axial tomography (CAT). These equipment do not show small ovarian tumors well, but they can see larger tumors, and may be able to see if the tumor is growing into nearby structures. It can also find the enlarged lymph nodes, signs of cancer spread to the liver or other organs, or signs that an ovarian tumor is affecting the kidneys or bladder. Furthermore, with the rising burden of ovarian cancer and technological advancements is expected to fuel the market growth over the forecast period.
To understand key trends, Download Sample Report
Among the North American region, the United States holds the highest share in the ovarian cancer diagnostics and therapeutics market and has contributed majorly for the same. Ovarian cancer is the ninth most common cancer and the fifth leading cause of cancer death among women in the United States. According to American Cancer Society estimates, in 2020, about 21,750 new cases of ovarian cancer will be diagnosed and 13,940 women will die of ovarian cancer in the United States. Furthermore, most of the top global ovarian cancer diagnostics players are headquartered in the United States and this tends to be the major advantage for the region, which is expected to drive the market.
To understand geography trends, Download Sample Report.
The ovarian cancer diagnostics and therapeutics market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. Key players in the market include AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffman-La Roche Ltd, GlaxoSmithKline Plc, Johnson and Johnson,Amneal Pharmaceuticals, and Siemens Healthineers AG among others.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Ovarian Cancer
4.2.2 Use of Combination Therapies for the Treatment of Ovarian Cancer
4.3 Market Restraints
4.3.1 Lack of Accurate Diagnosis of Ovarian Cancer
4.3.2 Lack of Awareness in Emerging and Low Income Economies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Cancer Type
5.1.1 Epithelial Ovarian Tumors
5.1.2 Ovarian Germ Cell Tumors
5.2 By Modality
220.127.116.11 Blood Tests
18.104.22.168 CT Scan
22.214.171.124 Other Diagnosis
126.96.36.199 Radiation Therapy
188.8.131.52 Hormonal Therapy
5.3.1 North America
184.108.40.206 United States
220.127.116.11 United Kingdom
18.104.22.168 Rest of Europe
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
188.8.131.52 South Africa
184.108.40.206 Rest of Middle-East and Africa
5.3.5 South America
220.127.116.11 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Amneal Pharmaceuticals LLC
6.1.2 Astrazeneca plc
6.1.3 Boehringer Ingelheim International GmbH
6.1.4 Bristol Myers Squibb Company
6.1.5 Eli Lilly and Company
6.1.6 F. Hoffman-La Roche Ltd
6.1.7 Glaxosmithkline Plc
6.1.8 Johnson and Johnson (Janssen Pharmaceuticals)
6.1.9 Pfizer Inc.
6.1.10 Siemens Healthineers AG
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments